Redwood AI

CSE: AIRX | OTCQB: RDWCF | FSE: YON



AI Platform for Quantum Security, Defense, Pharmaceutical Development, and Chemical Intelligence

October 2026

DISCLAIMER

Forward-Looking Information

This presentation may contain "forward-looking information" within the meaning of applicable Canadian securities legislation ("forward-looking statements") with respect to Redwood AI Corp. (the "Company"). All information, other than statements of historical facts, included in this presentation that addresses activities, events or developments that the Company expects or anticipates will or may occur in the future, including such things as future business strategy, competitive strengths, goals, expansion and growth of the Company's business, operations, plans and other such matters, is forward-looking information. By their nature, forward-looking statements are subject to a variety of factors that could cause actual results to differ materially from the results suggested by the forward-looking statements. In addition, forward-looking statements require the Company to make assumptions and are subject to inherent risks and uncertainties. There is significant risk that the forward-looking statements will not prove to be accurate, that the Company's assumptions may not be correct and that actual results may differ materially from those projected in such forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. Generally forward-looking statements can be identified by the use of terminology such as "anticipate", "believe", "will", "may", "could", "plan", "potential" and similar expressions.

Forward-looking statements contained in this presentation and other forward-looking statements are based on the opinions, estimates and assumptions of the Company's management in light of its experience and perception of historical trends, current conditions and expected future developments, as well as other factors that management currently believes are appropriate and reasonable in the circumstances. Such assumptions include the availability of sufficient capital, personnel, computing infrastructure and data; the successful integration of Quantum.IQ; the continued development and technical validation of the Company's technologies; the Company's ability to lawfully obtain, retain and use data to develop its technologies; customer acceptance of the Company's technologies; the continued adoption of post-quantum cryptographic standards; and the absence of material adverse technical, cybersecurity, regulatory or intellectual property developments. Despite a careful process to prepare and review the forward-looking statements, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. Forward-looking statements contained in this presentation include, but are not limited to, statements with respect to: the Company's business strategy, objectives, future operations, growth and expected future developments; the integration of Quantum.IQ and the development and commercialization of the Quantum.IQ platform and related technologies; the expected benefits, synergies and opportunities resulting from the acquisition of Quantum.IQ; the development, functionality, performance and commercial potential of the Company's artificial intelligence and chemical intelligence technologies and the Quantum.IQ platform, including its post-quantum cybersecurity capabilities; the Company's ability to develop, enhance and commercialize Quantum Defence and Quantum Offence capabilities; the adoption of post-quantum cryptography and evolving cybersecurity, compliance and critical infrastructure requirements; the Company's ability to identify and pursue opportunities with government, defense, public safety, financial services, pharmaceutical, biotechnology, critical infrastructure and other enterprise customers; the Company's subscription-based software-as-a-service and enterprise commercialization strategies; the development and expansion of the Company's proprietary datasets, models and technology; the Company's ability to develop AI-enabled candidate generation and broader chemical intelligence capabilities; future corporate transactions, acquisitions, financings and strategic partnerships; the expected benefits of transactions; future market trends and opportunities in pharmaceuticals, drug discovery, chemical manufacturing, CDMO, artificial intelligence, defense, cybersecurity, post-quantum security and critical infrastructure; the anticipated collection and use of deployment data and the expected effect of additional data on model performance; future customer engagements, pilots, deployments and adoption of the Company's technologies; the anticipated accuracy, speed, efficiency, cost, yield, scalability and other performance characteristics of the Company's technologies; the development and potential commercialization of proprietary drug candidates; management personnel, advisors and consultants; and the Company's current and future market position.

Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: the Company's ability to successfully integrate Quantum.IQ and realize the anticipated benefits and synergies of the acquisition; the ability to develop, enhance and commercialize the Company's technologies and platforms; the ability of the Company's artificial intelligence and chemical intelligence technologies and the Quantum.IQ platform, including its post-quantum cybersecurity capabilities, to perform as expected or achieve commercial adoption; changes in cybersecurity threats, cryptographic standards, post-quantum computing technologies, regulatory requirements or industry standards; competition from existing and emerging technology providers; cybersecurity incidents, data security breaches and vulnerabilities affecting the Company or its technologies; the ability to protect and maintain intellectual property and proprietary technology; the ability to attract and retain customers, strategic partners, employees and consultants; the ability to establish and maintain subscription-based, enterprise or other revenue models; the ability to market and sell the Company's products and services; risks associated with government, defense, public safety and critical infrastructure customers and procurement processes; risks associated with research, development and commercialization activities; the Company's market opportunities and estimates thereof being subject to significant uncertainty; the Company's ability to identify or complete acquisitions and successfully integrate acquired businesses and technologies; the Company's financial position and results of operations differing materially from expectations; the Company incurring future losses or failing to generate sufficient revenues; the need for additional capital; fluctuations in the market price and liquidity of the Company's securities; regulatory approvals and requirements; data protection and privacy laws and regulations; the ability to maintain effective internal controls; unfavorable global economic, political or market conditions; the Company's inability to obtain, retain or lawfully use sufficient data to develop and improve its technologies; the failure of additional deployment data to improve model performance as anticipated; the inaccuracy of performance measurements or third-party market data and forecasts; and other risks discussed in documents filed by the Company with Canadian securities regulatory authorities, which are available under the Company's profile on SEDAR+.

The Company and its directors, officers and employees disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable law. Accordingly, readers should not place undue reliance on forward-looking statements due to the inherent uncertainty therein. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Unless otherwise specified, all dollar amounts referenced herein are expressed in United States dollars.

Market & Industry Data

This presentation also contains references to certain market, industry and peer group data which is based upon information from independent industry publications, market research, analyst reports and surveys and other publicly available sources. Although the Company believes these sources to be generally reliable, such information is subject to interpretation and cannot be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other inherent limitations and uncertainties. The Company has not independently verified any of the data from third-party sources referred to in this presentation and accordingly, the accuracy and completeness of such data is not guaranteed.

No securities regulatory authority has expressed an opinion about the securities and it is an offence to claim otherwise. An investment in the securities of the Company is speculative and involves a high degree of risk. There are certain risk factors associated with an investment in the Company's securities and these risk factors should be reviewed carefully and evaluated by readers. Investments in technology issuers, including issuers developing AI and cybersecurity technologies, involve a significant degree of risk. An investment in these securities should only be made by persons who can afford the total loss of their investment

COMPANY OVERVIEW


Redwood AI is a post-quantum cybersecurity and artificial intelligence company developing technologies for defense, national security and other mission-critical applications.

Redwood's AI-powered Quantum.IQ platform enables organizations to discover cryptographic risk, accelerate post-quantum readiness, automate compliance, and strengthen critical infrastructure.

Redwood's AI-powered Reactosphere platform is designed to help organizations analyze complex chemical data, optimize chemical processes, design new molecules, and generate scientific insights.

Redwood's technologies support mission-critical applications across several strategic sectors:

- Quantum Cybersecurity & Critical Infrastructure Protection
- Defense, Public Safety & National Security
- Pharmaceutical Development & Drug Discovery
- Chemical Synthesis & Manufacturing
- Advanced Materials & Industrial Chemistry




WHAT IS QUANTUM.IQ?

Quantum.IQ, a subsidiary of Redwood AI, develops the Quantum.IQ platform, combining post-quantum cybersecurity with artificial intelligence to help organizations discover cryptographic assets, assess quantum readiness, automate compliance, and modernize security infrastructure.

Through its Quantum Defence and Quantum Offence capabilities, the platform supports the post-quantum security lifecycle, from cryptographic risk assessment and migration to continuous compliance verification.

Key Capabilities

- Cryptographic Asset Discovery & CBOM[1]
- Quantum Readiness Assessment
- AI-Assisted PQC[2] Migration
- Compliance & Risk Management
- Continuous Verification



1. Cryptographic Bill of Materials
2. Post-Quantum Cryptography

THE QUANTUM THREAT

As quantum computers advance toward Q-Day[1], widely used cryptographic systems face growing vulnerability. The time to prepare is now.

The Quantum Threat is Real

Encryption breaks

Quantum computing has the potential to render widely used cryptographic standards vulnerable, putting sensitive data, digital transactions, and critical systems at risk.

Harvest now, decrypt later

Threat actors are intercepting and storing encrypted data today to decrypt with quantum computers tomorrow.

Complex migration

Transitioning complex enterprise environments to new post-quantum cryptographic standards can require years of planning, migration, and compliance work.

The transition to post-quantum security is not simply a future technology challenge. Organizations need visibility into their cryptographic infrastructure today to prepare for the risks of tomorrow.

1. Q-Day refers to the point at which a cryptographically relevant quantum computer becomes capable of compromising vulnerable cryptographic systems. (UK Department for Science, Innovation and Technology, 2025)

THE QUANTUM SECURITY CHALLENGE

Limited Visibility Into Security Risks

- Organizations often do not know where encryption is used across their systems.
- Hidden vulnerabilities can be difficult to identify.
- Security gaps may increase operational and compliance risks.
- Organizations often lack a complete inventory of cryptographic assets and dependencies.

Preparing for Future Security Requirements

- The “Harvest-Now, Decrypt-Later” threat model is increasing the urgency for organizations to identify cryptographic risk and prepare for post-quantum security requirements.
- Organizations are assessing their readiness for future security requirements.
- Protecting sensitive information is becoming increasingly important.

Compliance & Security Modernization

- Governments, critical infrastructure operators, and regulated enterprises face increasingly stringent cybersecurity requirements.
- Security frameworks such as ITSG-33, GC ITSM, SOC 2 and NIST PQC are becoming important benchmarks for protecting sensitive systems and data.
- Organizations require continuous visibility, compliance, and infrastructure modernization to meet evolving security expectations.



THE QUANTUM.IQ SOLUTION

AI-powered end-to-end automation for discovering, inventorying, assessing, remediating, and continuously verifying cryptographic infrastructure.

Discovery & CBOM

- Discover and inventory cryptographic assets to create a complete view of an organization's encryption infrastructure.

Quantum Readiness & Mapping

- Identify cryptographic vulnerabilities, assess quantum readiness, and align systems with emerging security standards.

Harvest-Now, Decrypt-Later Risk Mitigation


- Identify vulnerable encryption protecting sensitive data and support prioritized post-quantum migration planning.

AI-Assisted Remediation

- Accelerate post-quantum migration and security modernization through AI-assisted remediation workflows.

Continuous Compliance & Verification

- Generate evidence, automate compliance workflows, and support alignment with leading security frameworks and audit requirements.



HOW QUANTUM.IQ WORKS

End-to-End Automation.

A continuous loop that discovers, inventories, maps, remediates, and verifies your cryptographic infrastructure.

01

Discovery

Scans certificates, TLS[1] configurations, APIs[2], and source code across your estate.

02

Inventory

Live Cryptographic Bill of Materials (CBOM)—inventories every key, certificate, and cipher.

03

Mapping

Aligns systems with NIST[3] PQC[4], Canadian GC ITSM[5] standards, and global cryptographic best practices.

04

Remediation

AI agents generate PQC migration PRs[6] (Kyber, Dilithium) with automated code refactoring and testing guidance.

05

Verification

Continuous monitoring and automated compliance evidence for NIST PQC, SOC 2[7], and Canadian federal standards (ITSG-33[8]).

ASSURANCE LIFECYCLE

1. Transport Layer Security.
2. Application Programming Interface.
3. National Institute of Standards and Technology.
4. Post-Quantum Cryptography,
5. GC – Government of Canada; ITSM.40.001 – Roadmap for the Migration to Post-Quantum Cryptography for the Government of Canada, Canadian Centre for Cyber Security.
6. Pull Requests - Proposed software code changes submitted for review and approval.
7. System and Organization Controls 2.
8. Information Technology Security Guidance Publication 33, IT Security Risk Management: A Lifecycle Approach.

A DUAL-SIDED QUANTUM SECURITY PLATFORM


Full-spectrum quantum security. Cryptographic defence to active threat simulation.

Quantum Defence:

- **Asset Discovery & CBOM** — identify and map cryptographic assets, keys, certificates, and dependencies across an organization
- **Quantum Readiness Mapping** — identify systems that may be vulnerable to future quantum computing threats
- **AI-Assisted PQC Migration & Automated Remediation** — help organizations modernize encryption and prepare for post-quantum security requirements
- **Continuous AI-Powered Compliance & Verification** — support ongoing compliance, audit readiness, and security reporting

Quantum Offence:

- **Quantum Pen Testing** — proactively test systems for potential quantum-related vulnerabilities
- **Attack Path Discovery** — identify how future quantum-enabled attacks could impact critical systems
- **Implementation Vulnerability Testing** — validate encryption implementations and security controls
- **Future Threat Simulation** — model emerging quantum security risks and evaluate organizational readiness



REDWOOD'S REACTOSPHERE

Redwood's Reactosphere platform applies artificial intelligence to complex chemical systems, molecular design, synthesis optimization, and scientific data analysis.

The Technology

- Reactosphere is a proprietary AI-powered chemistry platform that uses advanced chemical analysis and machine learning to model, predict, and optimize synthesis pathways, helping organizations accelerate discovery and development, improve decision-making, and solve complex scientific and operational challenges more efficiently.
- As the platform scales, each deployment expands Redwood's proprietary synthesis and reaction dataset. This growing data foundation improves model performance.

The Platform

- Reactosphere enables users to evaluate chemical pathways, optimize reactions, design molecules, and generate insights from complex scientific data.

Commercialization Strategy

- Redwood aims to commercialize its platform through a subscription-based software-as-a-service model, initially focused on pharmaceutical and biotechnology organizations.

Redwood AI intends to expand toward AI-enabled candidate generation and broader chemical intelligence capabilities, leveraging its growing proprietary data foundation.



REACTOSPHERE'S CAPABILITIES

Molecular Design

- AI-driven tools support the design and evaluation of novel molecules and materials.

Chemical Intelligence & Hazard Analysis


- Analyzes chemical data to identify hazards, assess risks, and support safety and security decision-making.

Process Optimization

- Optimization algorithms identify reaction conditions that improve yield, purity, and efficiency.

Synthesis Intelligence


- Models trained on billions of reactions predict efficient synthesis routes and evaluate alternative synthetic pathways.



EXISTING TECHNOLOGY – SCALE AND ACCURACY

Conventional

Target molecule for analysis




Manual Process

Target molecule must be manually reviewed, with potentially thousands of starting materials.

***Multi-week** planning per attempt*

- Manual review cannot be scaled.
- Operational costs for multi-chemist review means either long turnaround times or high project costs.
- Fewer options and contingencies are considered.



AI-Assisted

Redwood AI Model Process

Multiple pathways generated.
Less than **1 minute** per pathway.
~**95%** model accuracy.
Abbreviated manual review.

- The model is proprietary and uses large language models trained on over 1 billion molecules and 4 million reactions.
- Every step of the synthesis is automatically cost- and vendor-evaluated from 60+ global sources.
- Safety and environmental predictions included.

WHY INDUSTRIES NEED AI-POWERED CHEMICAL INTELLIGENCE

Complexity Is Increasing

- Modern medicines, materials, and scientific processes are becoming increasingly complex to design, analyze, and manufacture.[1]

Data Is Growing Rapidly

- Large volumes of scientific and experimental data require advanced tools to analyze and extract insights.[2]

Faster Development Is Critical

- Companies and governments need faster ways to discover medicines, develop materials, identify emerging risks, and improve manufacturing efficiency.[3]
- Drug development and chemical innovation remain slow and resource intensive, creating strong demand for technologies that can accelerate research and development.



Source 1: https://pmc.ncbi.nlm.nih.gov/articles/PMC10544322/
Source 2: https://pmc.ncbi.nlm.nih.gov/articles/PMC12333164/
Source 3: https://www.frontiersin.org/journals/drug-discovery/articles/10.3389/fddsv.2023.1201419/full

AN INTEGRATED AI TECHNOLOGY PLATFORM

Redwood's integrated technology portfolio combines its Quantum.IQ platform, focused on AI-enabled post-quantum cybersecurity, with its Reactosphere chemical intelligence platform to address opportunities across defense, national security, enterprise cybersecurity, critical infrastructure, pharmaceutical development and industrial markets.

Quantum.IQ


- Cryptographic Discovery & CBOM
- Quantum Readiness & PQC Migration
- Compliance, Risk Management & Continuous Verification
- Quantum Defence & Quantum Offence

Reactosphere

- Molecular Design
- Chemical Intelligence & Hazard Analysis
- Synthesis Intelligence
- Process Optimization

Integrated Technology Platform

- Pharmaceutical Development & Drug Discovery
- Defense, Public Safety & National Security
- Quantum Security & Critical Infrastructure Protection
- Chemical Manufacturing & Industrial Chemistry





STRATEGIC APPLICATION AREAS

Quantum Security & Critical Infrastructure

- AI-powered tools supporting cryptographic discovery, post-quantum readiness, compliance automation, and security modernization.
  - **Example:** Help organizations create a cryptographic inventory (CBOM), assess quantum readiness, and support compliance with evolving security standards.

Defense & Strategic Applications

- AI-powered chemical intelligence and hazard analysis supporting threat assessment, safety monitoring, and decision-making.
  - **Example:** Identify unknown compounds or hazardous materials more quickly, reducing laboratory testing time and cost.

Government, Public Safety & Law Enforcement


- Chemical data analysis to support hazardous material detection, border security, and safety monitoring.
  - **Example:** AI-assisted detection and analysis of toxic opioids and hazardous substances supporting public safety initiatives involving the government, the RCMP, and other law enforcement partners.

Pharmaceutical Development & Drug Discovery

- AI-driven analysis of chemical datasets to accelerate drug discovery, molecular design, and future candidate generation.
  - **Example:** Identify promising drug candidates earlier in the discovery process.

Chemical Manufacturing & Process Optimization

- AI tools for optimizing synthesis pathways, improving process efficiency, and supporting manufacturing scalability.
  - **Example:** Identify lower-cost synthesis routes that improve yield, efficiency, and production performance.



MARKET OPPORTUNITY




Redwood operates across post-quantum cybersecurity, defense and public safety, pharmaceutical development and AI-enabled drug discovery, and advanced chemical and molecular sciences, creating exposure to several large and rapidly growing global markets.

- Exposure to the ~$2.7T USD (2024) global defense spending market, projected to exceed ~$6.3T by 2035 as AI and advanced analytics become increasingly embedded in national security systems.[1]
- Embedded within the $1.65T USD (2024) global pharmaceutical market, projected to exceed ~$2.35T USD by 2030.[2]
- Exposure to the ~$271.9B USD (2025) global cybersecurity market, projected to reach approximately $663.2B USD by 2033, with a strategic focus on post-quantum security, cryptographic discovery, post-quantum readiness, compliance automation, and critical infrastructure modernization.[3]
- Operates within the $197.4B+ USD global CDMO market, projected to grow ~$392.67B USD by 2035.[4]
- Exposure to the $6.9B USD (2025) AI-enabled drug discovery market, projected to reach ~$17.81B USD by 2035.[5]

Source 1: https://www.sphericalinsights.com/press-release/defence-spending-market
Source 2: https://www.grandviewresearch.com/industry-analysis/pharmaceutical-market-report
Source 3: https://www.grandviewresearch.com/industry-analysis/cyber-security-market
Source 4: https://www.precedenceresearch.com/pharmaceutical-cdmo-market
Source 5: https://www.precedenceresearch.com/artificial-intelligence-in-drug-discovery-market

AI AND CHEMICAL INTELLIGENCE IN DEFENSE APPLICATIONS



Source: https://www.sphericalinsights.com/press-release/defence-spending-market

AI adoption across defense and national security systems is accelerating, increasing demand for advanced analytics and chemical intelligence capabilities.

Market Growth

- The global defense spending market is projected to grow from ~$2.7T in 2024 to ~$6.38T by 2035.[1]
- Governments worldwide are increasing investment in AI, advanced analytics, and next-generation defense technologies.[1]


Why This Matters

- Defense organizations increasingly rely on AI-enabled systems to analyze complex datasets and support strategic decision-making.
- Chemical and materials intelligence plays an important role in national security, safety monitoring, and defense research programs.
- AI chemistry platforms can analyze chemical data to identify threats and support development of new materials used in defense systems.

Source 1: https://www.sphericalinsights.com/press-release/defence-spending-market

AI AND CHEMICAL INTELLIGENCE IN PHARMACEUTICAL DEVELOPMENT

Global Pharmaceutical Market Size
2020 to 2030 (USD Trillion)



Source: https://www.grandviewresearch.com/industry-analysis/pharmaceutical-market-report

AI adoption across pharmaceutical R&D is accelerating, creating opportunities for advanced chemical intelligence across the drug development lifecycle.

Market Growth

- The global pharmaceutical market was approximately $1.65T USD in 2024 and is projected to exceed ~$2.35T USD by 2030.[1]
- Growth in pharmaceutical R&D is increasing demand for technologies that can improve discovery, synthesis planning, and development efficiency.


Why This Matters

- Pharmaceutical development requires the analysis of increasingly complex molecular, chemical, and experimental data.
- AI-powered chemical intelligence can accelerate molecular analysis, synthesis planning, and optimization while enabling broader exploration of potential development pathways.
- Redwood's technologies can support pharmaceutical and biotechnology organizations across molecular design, synthesis intelligence, process optimization, and AI-enabled candidate generation.

Source 1: https://www.grandviewresearch.com/industry-analysis/pharmaceutical-market-report

QUANTUM SECURITY AND CRITICAL INFRASTRUCTURE

Cybersecurity Market
Size, by Offering, 2023-2033 (USD Billion)



Source: https://www.grandviewresearch.com/industry-analysis/cyber-security-market

Adoption of post-quantum security initiatives is accelerating, increasing demand for cryptographic discovery, post-quantum readiness, and infrastructure modernization solutions.

Market Growth


- The global cybersecurity market is projected to grow from approximately $271.9B USD in 2025 to ~$663.2B USD by 2033.[1]
- Governments, defense organizations, financial institutions, and critical infrastructure operators are investing heavily in post-quantum security as compliance frameworks and national security requirements continue to evolve.

Why This Matters

- Governments, defense organizations, financial institutions, and critical infrastructure operators are investing heavily in post-quantum security as frameworks such as ITSG-33, NIST PQC, GC ITSM, and SOC 2 become increasingly important for protecting critical systems and demonstrating compliance.
- Government, defense, financial services, and critical infrastructure sectors face growing pressure to evaluate quantum readiness.
- The Quantum.IQ platform combines artificial intelligence with post-quantum cybersecurity to help organizations discover cryptographic assets, assess quantum readiness, automate remediation, continuously verify compliance and modernize security infrastructure.

Source 1: https://www.grandviewresearch.com/industry-analysis/cyber-security-market

AI ACCELERATION IN THE GLOBAL CDMO MARKET



AI adoption in drug manufacturing and development is accelerating, creating a structural opportunity within the global CDMO market.

Market Growth


- The global CDMO market is projected to grow from $197.4B USD in 2025 to ~$392.67B USD by 2035.[1]

Why This Matters

- CDMOs underpin drug development and commercialization infrastructure.[2]
- Increasing molecule complexity and biologics demand require more advanced synthesis planning and scalable manufacturing solutions.[2]
- Redwood's AI-powered chemistry platform can improve synthesis planning, reduce costs, and increase manufacturing scalability within CDMO infrastructure.

Source 1: https://www.precedenceresearch.com/pharmaceutical-cdmo-market
Source 2: https://pharmaceuticalmanufacturer.media/pharmaceutical-industry-insights/latest-pharmaceutical-manufacturing-industry-insights/pharma-outsourcing-trends-2025-partnership-precision-and-res/
Source 3: https://www.contractpharma.com/exclusives/ai-in-pharma-manufacturing-trends-applications-shortening-timelines/

AI IN DRUG DISCOVERY AND MOLECULAR DESIGN



Source: https://www.precedenceresearch.com/artificial-intelligence-in-drug-discovery-market

AI adoption is accelerating in early discovery, molecular design, and candidate prioritization.

Market Growth

- The global AI in drug discovery market is projected to grow from $6.9B USD in 2025 to ~ $17.81B USD by 2035.[1]
- Forecasts consistently show double-digit growth as AI becomes embedded in early-stage discovery and design.[1]

Why This Matters

- Early-stage discovery and molecular design require significant time, cost, and repeated testing.
- AI enables broader exploration of chemical space and faster prioritization.
- Platforms that combine synthesis intelligence with discovery and candidate prioritization can improve efficiency across the drug development lifecycle.

Potential Strategic Upside

- AI-enabled discovery platforms also have the potential to generate proprietary drug candidates, enabling participation in drug sales and access to the significantly larger global pharmaceutical market.

Source 1: https://www.precedenceresearch.com/artificial-intelligence-in-drug-discovery-market

COMPARABLE COMPANIES

Company	Market Cap / Capital Raised (USD)	Focus	Notes
Palantir	**$411B Market Cap**	AI Platforms / Defense	**AI data and analytics platform used by governments, defense agencies, and enterprises.** **Widely deployed across national security, intelligence, and defense applications.**
QUANTINUUM	**$18.76B Market Cap**	Quantum Computing / Cybersecurity	**Full-stack quantum computing company developing advanced quantum hardware and software solutions.** **Commercial applications span cybersecurity, drug discovery, materials science, AI and other enterprise use cases.**
ANDURIL	**$3B+ Raised**	Defense AI	**AI-driven defense technology company developing autonomous systems and defense platforms.** **Focus on AI-enabled national security and military applications.**
Insilico Medicine	**$3.24B* Market Cap**	Generative Drug Discovery	**AI driven generative drug discovery platform.** **AI designed candidates advanced to clinical trials.**
RECURSION	**$1.76B Market Cap**	AI Drug Discovery	**AI for drug discovery platform.** **Publicly listed with major pharma partnerships.**

Source: Publicly available financing disclosures, company press releases, regulatory filings, and third-party databases. Market capitalization and funding figures are estimated as of August 11, 2026.
* HKEX market data; currency conversion based on Bank of America exchange rates as of August 11, 2026.

WHO WE ARE

- Two successful private company exits and multiple IPOs.
- Experience ranging from chemistry and data science to financing.
- Affiliations with top US and Canadian Universities.
- Public company experience, listings on NASDAQ, CSE, TSX and TSX-V.

Redwood Team



Louis Dron, MSc
CEO




Kristian Thorlund, PhD
President & Director



Glenn Sammis, PhD
Head of Chemistry



Mark R. Dybul, MD
Public Safety & Defense Advisor



Ofir Harari, PhD
Head of AI



Prince Lat, PhD
Senior Data Scientist



Joey Lai
Research Scientist



Matthew A. Roberts, PhD
Public Safety & Defense Advisor

Directors & Officers



Nico Mah
CFO & Corporate Secretary



Masoud Darbandi
Director



Sam Shahrokhi
Director



Matthew Mingay
Director

REDWOOD TEAM



Louis Dron, MSc

Mr. Dron is a healthcare executive with multidisciplinary experience spanning clinical science, health technology, and leadership roles across corporate and research settings. His background includes clinical diagnostics and leading research teams focused on real-world evidence in healthcare. He began his career at the UK National Health Service, later transitioning into senior research and development leadership roles integrating real-world evidence, biostatistics, and epidemiology into healthcare decision-making. Mr. Dron also serves as an advisor to the Canadian Drug Agency and the Bill & Melinda Gates Foundation and is a graduate of the University of Manchester and the University of Leicester.



Kristian Thorlund, PhD
President & Director

Dr. Thorlund, with over 15 years of experience in data science and AI, is an established serial entrepreneur having been involved in the foundation of five Canadian-based businesses, with two successful multi-million dollar exits, over the past decade focused on health technologies. Kristian is an expert in AI and data analysis, ranking within the top 1% of researchers in his field worldwide by citation count. Alongside his business interests, Kristian is a part-time professor at McMaster University, acquiring over $6 million in grants. He has also held an academic appointment at Stanford University and has collaborated extensively with the Bill & Melinda Gates Foundation. He is a graduate of the University of Copenhagen and McMaster University.



Glenn Sammis, PhD
Head of Chemistry

Dr. Sammis is a worldwide leader in chemistry, acting as an accomplished academic with nearly two decades of experience. Currently, a professor at the University of British Columbia, he has built an exceptional teaching record, excelling across a wide range of courses, student evaluations, course development, creation of innovative materials, and teaching leadership. At his time at UBC, Dr. Sammis has acquired over $5.5m in grants. Outside of his research group being at the forefront of pioneering advances in radical and photochemical processes, Glenn has acted as an advisor for synthesis problems for over 10 private companies. He is a graduate of Stanford University and Harvard University.



Ofir Harari, PhD
Head of AI

Dr. Harari is a highly experienced statistician and data scientist with over 15 years of experience across various industries, including healthcare, pharmaceuticals, finance and academia. He has a proven track record in both practical data analysis and methodological research, consistently mentoring teams and advancing innovative solutions in healthcare, AI, and statistical science. In recent years, in addition to his tenure at Redwood AI, he served as a Head of Biostatistics at Purpose Life Science and has previously worked for PayPal. He is a graduate of Ben Gurion University and Tel Aviv University.



Prince Lat, PhD
Senior Data Scientist

Dr. Lat is a passionate researcher and data scientist with a decade of experience. His research spans multiple disciplines, including bioinformatics, biophysics, biochemistry, molecular biology, and DNA nanotechnology. He has also worked in biostatistics and data science, applying these tools to extract insights from complex datasets. He is a graduate of IIT Kanpur and Simon Fraser University.

REDWOOD TEAM CONT'



Nico Mah
CFO & Corporate Secretary

Mr. Mah is a Chartered Professional Accountant and has nearly 8 years of experience in auditing and public accountancy, having been an associate and subsequently a manager at PricewaterhouseCoopers LLP, the global audit and assurance, tax, deals and consulting firm from September 2015 to January 2023. He holds a Bachelor of Commerce degree, majoring in Accounting, from the University of Calgary and a CPA designation in Alberta, Canada.



Sam Shahrokhi
Director

Mr. Shahrokhi is an accomplished entrepreneur and business development executive with broad experience across the health, biotechnology, and mining industries. Over the course of his career, he has held numerous leadership roles and has been involved with a variety of successful private and public companies. Recognized for his strategic vision and ability to identify emerging opportunities, Mr. Shahrokhi has played an important role in helping businesses scale, strengthen their market position, and create long-term shareholder value.



Masoud Darbandi
Director

Mr. Darbandi is a sales strategist with over 30 years of experience leading national distribution and client relations across the professional wellness industry. He has driven growth for established brands including WELLA, AMERICAN CREW, and NIOXIN and brings experience in commercialization, customer engagement, and brand development within complex stakeholder environments.



Matthew Mingay
Director

Mr. Mingay is a Research Data Scientist at Lawrence Berkeley National Laboratory (UC Berkeley) working at the intersection of biotechnology, computer science, and artificial intelligence. He has over ten years of experience in molecular biology and data science and has contributed to peer-reviewed research in areas including cancer genomics and epigenetics.

REDWOOD TEAM CONT'



Mark R. Dybul, MD
Public Safety & Defense Advisor

Dr. Dybul is a physician, scientist, and internationally recognized public health leader with more than two decades of experience in infectious disease research, global health policy, and large-scale healthcare program implementation. He served as United States Global AIDS Coordinator under President George W. Bush, where he led the implementation of the President's Emergency Plan for AIDS Relief (PEPFAR), one of the largest international health initiatives in history. Dr. Dybul held the rank of Rear Admiral in the U.S. Public Health Service and served as Assistant U.S. Surgeon General, reflecting his leadership in national and global public health initiatives.



Matthew A. Roberts, PhD
Public Safety & Defense Advisor


Over the course of his 25-year career, Dr. Roberts has held senior executive roles at leading companies including Nestlé, Abbott, Pharmavite, and Niagen Bioscience. His experience includes establishing a corporate venture fund at Nestlé focused on health innovation, co-leading at Abbott a public-private partnership with the University of Illinois that helped create the Center for Nutrition, Learning, and Memory, and expanding external research efforts at Niagen Bioscience, formerly ChromaDex, in support of peer-reviewed publications, regulatory progress, and new business areas focused on mitochondrial health. Dr. Roberts holds a Ph.D. in Toxicology from Cornell University, an MBA from Washington University in St. Louis, and a B.Sc. in Molecular Biology from Purdue University.

QUANTUM.IQ TEAM




Kevin O'Neill
CEO of Quantum.IQ

Mr. O'Neill is the Chief Executive Officer of Quantum.IQ Technologies, bringing more than 35 years of experience in technology investing, advisory and leadership. Previously, He has co-founded numerous technology companies, including: Teleo Communications, acquired by Microsoft; Workfire Technologies, acquired by Packeteer; and Xtract AI Technologies, acquired by Patriot One; M37 Technology Partners; Railtown AI Technologies; and InMotion Energy Systems.



Dr. Elliot Holtham
CTO of Quantum.IQ

Dr. Holtham (PhD Computational Science) is the Chief Technology Officer of Quantum.IQ Technologies, bringing more than 20 years of experience in technology invention, development and leadership. He has also co-founded numerous technology companies, including: Xtract AI Technologies, acquired by Patriot One; M37 Technology Partners; Railtown AI Technologies; and InMotion Energy Systems.



Paul Dadwal
Advisor

Mr. Dadwal is Founder and CEO of Ari & Co. Capital, a Vancouver-based private family-office. He is an entrepreneur and technology investor with experience across capital markets, early-stage technology companies and public safety, who served previously with the Royal Canadian Mounted Police as a Superintendent for more than 19 years, leading several high-profile law enforcement investigations. Mr. Dadwal has also received recognition including the International Association of Chiefs of Police 40 Under 40 Award, the Queen's Jubilee Medal and a Governor General's commendation.

REDWOOD AI HIGHLIGHTS

Expanding Market Opportunity

- AI-enabled chemical intelligence applications are increasingly relevant to defense and national security sectors, where global defense spending exceeds $2.7T (2024) annually.[1]
- Embedded within the $1.65T (2024) global pharmaceutical market, projected to exceed ~$2.35T by 2030.[2]
- Exposure to the ~$271.9B USD (2025) global cybersecurity market, projected to reach ~$663.2B by 2033.[3]

AI-Powered Technology

- Quantum.IQ provides Quantum Defence and Quantum Offence capabilities spanning cryptographic discovery, quantum readiness, AI-assisted PQC migration, compliance verification and future threat simulation.
- AI-powered chemistry platform, Reactosphere, designed to model, predict, and optimize chemical synthesis pathways.

Compounding Data Advantage

Each Reactosphere deployment captures structured synthesis and reaction data, expanding Redwood's proprietary dataset. This growing data foundation improves model performance over time and enables deeper chemical intelligence capabilities and future platform expansion.

Broad Applicability Across Critical Industries

- Quantum.IQ: Applicable across enterprise cybersecurity, government, defense, financial services and critical infrastructure, supporting cryptographic discovery, quantum readiness assessment, PQC migration planning, compliance verification and security modernization.
- Reactosphere: Applicable across pharmaceuticals, biotechnology, industrial chemistry and defense, supporting drug development, synthesis planning, intellectual property assessment and broader chemical intelligence use cases.

Clear Commercialization Strategy

- Quantum.IQ: Subscription-based SaaS and enterprise engagement model for organizations with digital infrastructure, with higher-value early opportunities across defense, public safety, financial institutions, government and biopharma.
- Reactosphere: Subscription-based SaaS platform focused on pharmaceutical and biotechnology organizations, with expansion toward AI-enabled candidate generation and broader drug pipeline support.

Experienced Leadership Team

Led by a multidisciplinary team with expertise in artificial intelligence, data science, chemistry, healthcare, cybersecurity, cryptographic security and post-quantum readiness, supported by academic and industry experience.



Source 1: https://www.sphericalinsights.com/press-release/defence-spending-market
Source 2: https://www.grandviewresearch.com/industry-analysis/pharmaceutical-market-report
Source 3: https://www.grandviewresearch.com/industry-analysis/cyber-security-market

CAPITAL STRUCTURE

As of October 2, 2026

Common Shares Issued & Outstanding:	**51,650,895**
Warrants:	**4,289,866**
Issued & Outstanding Fully Diluted:	**61,711,761**

CSE: AIRX

OTCQB: RDWCF

FSE: YON

Redwood AI

Contact

Address:

1309-7th Street SW
Calgary, AB, T2R 1A5
Canada

investors@redwoodai.com

www.redwoodai.com